<DOC>
	<DOCNO>NCT00766688</DOCNO>
	<brief_summary>The present study assess efficacy safety AVE5530 ( 25 mg 50 mg ) add-on ongoing treatment high dos statin double-blind manner comparison placebo , management patient severe primary hypercholesterolemia consider inadequately control despite ongoing statin treatment . The main objective evaluate effect association AVE5530+statin LDL-C level reduction 12 week treatment . The effect AVE5530 lipid parameter assess secondary objective .</brief_summary>
	<brief_title>Evaluation Safety Efficacy AVE5530 add-on Ongoing High Doses Statins Patients With Primary Severe Hypercholesterolemia</brief_title>
	<detailed_description>The two dos AVE5530 test study 25 mg 50 mg take evening , dinner dosing . The study include pre-randomization phase 6 week , double-blind treatment period least 12 month variably extend approximately 18 month .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Adults severe primary hypercholesterolemia cholesterol level control ongoing stable statin treatment maximum dos . LDLC level &gt; 250 mg/dL ( 6.48 mmol/L ) &lt; 100 mg/dL ( 2.59 mmol/L ) Triglycerides &gt; 350 mg/dL ( 3.95 mmol/L ) Conditions / situation : Presence clinically significant uncontrolled endocrine disease know influence lipid level Active liver disease Recent history congestive heart failure , unstable angina pectoris , myocardial infarction , coronary bypass surgery angioplasty , Unstable severe peripheral artery disease Positive test Hepatitis B surface antigen and/or Hepatitis C antibody Known Human Immunodeficient Virus ( HIV ) positive Pregnant breastfeeding woman , Women childbearing potential protected effective contraceptive method birth control ( include oral contraceptive ) and/or unwilling unable test pregnancy prior exposure Investigational Product The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>